SLC5A2 and diabetes mellitus: In addition, there were greater percentages of patients who received clopidogrel, beta-2 blockers, antiplatelet drugs, statins, and DM treatments such as metformin, thiazolidinedione, AGIs, DPP4is, and insulin among SGLT2 inhibitor users than among nonusers (Table 1).